Kuros Biosciences Announces Treatment of the First Patient in its Spinal Fusion Trial with Fibrin-PTH
September 01, 2020 01:00 ET
|
Kuros Biosciences
First investigational trial of a drug-biologic bone graft for spine fusionPhase 2 trial in the U.S. compares Fibrin-PTH (KUR-113) with local autograftPrimary endpoint is radiographic interbody fusion...
Kuros Biosciences Reports Results for First Half 2020
August 12, 2020 01:00 ET
|
Kuros Biosciences
Financial and Operational Highlights CHF 16.0 million cash & cash equivalents, trade and other receivables as at June 30, 2020Revenues increased to CHF 1.3 million driven by strong MagnetOs...
Kuros Biosciences Further Strengthens Orthobiologics Patent Portfolio
July 22, 2020 01:00 ET
|
Kuros Biosciences
Grant of European patent entitled ‘Osteoinductive composites’Notice of allowance of Japanese patent from the same patent familyFurther strengthens Kuros’s position as a leader in the field of...
Kuros Biosciences Reports Results for the Full Year 2019
March 26, 2020 02:00 ET
|
Kuros Biosciences
Financial highlights CHF 21.9 million cash & cash equivalents, trade and other receivables as at December 31, 2019Revenues increased to CHF 2.6 million Net operating costs decreased to CHF 13.5...
Kuros Strengthens Orthobiologics Patent Portfolio
March 18, 2020 02:00 ET
|
Kuros Biosciences
Grant of US patent covering the use of PTH containing matrices for spinal fusionGrant of US patent covering osteoinductive materials made by certain methodsFurther strengthens Kuros’s position as a...
Kuros Reports Publication of MagnetOs Preclinical Data Demonstrating Superiority to Market-Leading Synthetic Bone Grafts in Spinal Fusion
January 30, 2020 01:00 ET
|
Kuros Biosciences
Head-head study of spinal fusion versus the ‘best-in-class’ alternatives within categoryAccepted for publication in Clinical Spine Surgery – a surgeon focused journalPresented by leading academic...
Kuros Biosciences to Host Key Opinion Leader Meeting in Zurich Showcasing its Commercial Stage Advanced Bone Graft MagnetOs
October 02, 2019 12:00 ET
|
Kuros Biosciences
SCHLIEREN (ZURICH), Switzerland, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Kuros Biosciences, (SWX: KURN) a full-fledged orthobiologics company with scientific, clinical, and commercial excellence in bone...
Kuros Biosciences announces full commercial launch of MagnetOs™ and exhibitor status at North American Spine Society 34th Annual Meeting
September 24, 2019 01:00 ET
|
Kuros Biosciences
Kuros to fully launch MagnetOs™ at the North American Spine Society 34th Annual Meeting in Chicago, USA, September 25-28, building on the momentum gained during the initial phased launch. Kuros...
Kuros Biosciences Announces U.S. FDA approval of IND Application to Initiate Fibrin-PTH Phase 2a Clinical Trial in Spinal Fusion
September 03, 2019 01:00 ET
|
Kuros Biosciences
Kuros to conduct Phase 2a trial in spinal fusion, comparing Fibrin-PTH to autograftPrimary endpoint is radiographic interbody fusion at 12 months SCHLIEREN (ZURICH), Switzerland, Sept. 03, 2019 ...
Kuros Biosciences Reports Results for First Half 2019
August 20, 2019 07:00 ET
|
Kuros Biosciences
Financial highlights CHF 13.4 million cash and cash equivalents (including trade and other receivables) at June 30, 2019Product sales were CHF 0.9 million in the first half of 2019, a substantial...